Press Releases

March 26, 2024
Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients
March 5, 2024
Praxis Precision Medicines Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results
March 1, 2024
Praxis Precision Medicines to Participate in TD Cowen’s 44th Annual Health Care Conference
February 2, 2024
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 11, 2024
Praxis Precision Medicines, Inc. Announces Pricing of $150.0 Million Public Offering
January 8, 2024
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
January 5, 2024
Praxis Precision Medicines Announces Licensing and Collaboration Agreement with Tenacia Biotechnology for Ulixacaltamide in Greater China
Displaying 11 - 19 of 19